lipiarmycin A3 | 56645-60-4

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 大环内酯类和类似物
• 英文名称: lipiarmycin A3
• 英文别名: [(2R,3S,4S,5S,6R)-6-[[(3E,5E,9E,13E,15E)-12-[(2R,3S,4R,5S)-3,4-dihydroxy-6,6-dimethyl-5-(2-methylpropanoyloxy)oxan-2-yl]oxy-11-ethyl-8-hydroxy-18-(1-hydroxyethyl)-9,13,15-trimethyl-2-oxo-1-oxacyclooctadeca-3,5,9,13,15-pentaen-3-yl]methoxy]-4-hydroxy-5-methoxy-2-methyloxan-3-yl] 3,5-dichloro-2-ethyl-4,6-dihydroxybenzoate
• CAS: 56645-60-4
• 化学式: C₅₂H₇₄Cl₂O₁₈
• 分子量: 1058.05
• InChiKey: ZVGNESXIJDCBKN-OCTTYGFMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.4
• 重原子数：
  72
• 可旋转键数：
  15
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.63
• 拓扑面积：
  267
• 氢给体数：
  7
• 氢受体数：
  18

ADMET

毒理性

• 在妊娠和哺乳期间的影响

母乳喂养期间使用总结：目前没有关于母乳喂养期间使用(fidaxomicin)(fidaxomicin)的信息。由于口服吸收不良，它不太可能进入婴儿的血液或对哺乳婴儿产生任何不良影响。 对哺乳婴儿的影响：截至修订日期，没有找到相关的已发布信息。 对泌乳和母乳的影响：截至修订日期，没有找到相关的已发布信息。

◉ Summary of Use during Lactation:No information is available on the use of fidaxomicin during breastfeeding. Because it is poorly absorbed orally, it is not likely to reach the bloodstream of the infant or cause any adverse effects in breastfed infants. ◉ Effects in Breastfed Infants:Relevant published information was not found as of the revision date. ◉ Effects on Lactation and Breastmilk:Relevant published information was not found as of the revision date.

来源:Drugs and Lactation Database (LactMed)

反应信息

• 作为反应物：
  描述：

  lipiarmycin A3 在 氢氧化钾 作用下， 反应 20.0h， 生成
  参考文献：
  名称：

  Arnone, Alberto; Nasini, Gianluca; Cavalleri, Bruno, Journal of the Chemical Society. Perkin transactions I, 1987, p. 1353 - 1360

  摘要：

  DOI：

文献信息

• Tiacumicin production
  申请人：Optimer Pharmaceuticals, Inc.

  公开号：EP2860241A1

  公开（公告）日：2015-04-15

  Methods, processes and materials for the production and recovery of Tiacumicins produced by culturing a microorganism belonging to the species Dactylosporangium aurantiacum subspecies hamdenensis having the ability to produce and accumulate one or more Tiacumicin in a nutrient medium comprising a carbon source, a nitrogen source, trace elements such as inorganic salts, and an adsorbent, wherein said nitrogen source comprises fish powder, and wherein said Tiacumicin is produced in a yield greater than about 50 mg/L broth.

  用于生产和回收通过在营养培养基（包括碳源、氮源、微量元素（如无机盐）和吸附剂）中培养属于 Dactylosporangium aurantiacum 亚种 hamdenensis 的微生物而产生的烟曲霉毒素的方法、工艺和材料，该微生物具有生产和积累一种或多种烟曲霉毒素的能力，其中所述氮源包括鱼粉，并且所述烟曲霉毒素的产量大于约 50 mg/L 肉汤。
• TIACUMICIN PRODUCTION
  申请人：Optimer Pharmaceuticals, Inc.

  公开号：EP1539977B1

  公开（公告）日：2014-10-08
• MACROLIDE POLYMORPHS, COMPOSITIONS COMPRISING SUCH POLYMORPHS, AND METHODS OF USE AND MANUFACTURE THEREOF
  申请人：Chiu Yu-Hung

  公开号：US20080194497A1

  公开（公告）日：2008-08-14

  The invention relates to novel forms of compounds displaying broad spectrum antibiotic activity, especially crystalline polymorphic forms and amorphous forms of such compounds, compositions comprising such crystalline polymorphic forms and amorphous forms of such compounds, processes for manufacture and use thereof. The compounds and compositions of the invention are useful in the pharmaceutical industry, for example, in the treatment or prevention of diseases or disorders associated with the use of antibiotics, chemotherapies, or antiviral therapies, including, but not limited to, colitis, for example, pseudo-membranous colitis; antibiotic associated diarrhea; and infections due to Clostridium difficile (“ C. difficile ”), Clostridium perfringens (“ C. perfringens ”), Staphylococcus species, for example, methicillin-resistant Staphylococcus , or Enterococcus including Vancomycin-resistant enterococci.
• MACROCYCLIC POLYMORPHS, COMPOSITIONS COMPRISING SUCH POLYMORPHS, AND METHODS OF USE AND MANUFACTURE THEREOF
  申请人：Chiu Yu-Hung

  公开号：US20100081800A1

  公开（公告）日：2010-04-01

  The invention relates to novel forms of compounds displaying broad spectrum antibiotic activity, especially crystalline polymorphic forms and amorphous forms of such compounds, compositions comprising such crystalline polymorphic forms and amorphous forms of such compounds, processes for manufacture and use thereof. The compounds and compositions of the invention are useful in the pharmaceutical industry, for example, in the treatment or prevention of diseases or disorders associated with the use of antibiotics, chemotherapies, or antiviral therapies, including, but not limited to, colitis, for example, pseudo-membranous colitis; antibiotic associated diarrhea; and infections due to Clostridium difficile (“ C. difficile ”), Clostridium perfringens (“ C. perfringens ”), Staphylococcus species, for example, methicillin-resistant Staphylococcus , or Enterococcus including Vancomycin-resistant enterococci.
• Tiacumicin Production
  申请人：Optimer Pharmaceuticals, Inc.

  公开号：US20140296498A1

  公开（公告）日：2014-10-02

  Methods, processes and materials for the production and recovery of Tiacumicins produced by culturing a microorganism belonging to the species Dactylosporangium aurantiacum subspecies hamdenensis having the ability to produce and accumulate one or more Tiacumicin in a nutrient medium comprising a carbon source, a nitrogen source, trace elements such as inorganic salts, and an adsorbent, wherein said nitrogen source comprises fish powder, and wherein said Tiacumicin is produced in a yield greater than about 50 mg/L broth.